Biogenity ApS: Financial statements 2022
CVR: 39606925
Source: annual report 2022, Danish Business Authority
01/07/2021 – 30/06/2022
Biogenity ApS (CVR 39606925) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 1,251,021 and a net result of DKK -107,560 compared with DKK 117,322 the year before. That is an increase of 1,190% compared with the year before. Equity in the 2022 report amounted to DKK 142,578. The solvency ratio was 21.9%. The company had 5 employees in the financial year.
- Gross Profit
- DKK 1,251,021
- Profit/Loss
- DKK -107,560
- Equity
- DKK 142,578
- Total Assets
- DKK 650,459
- Employees
- 5
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 1.3 mio. | -108 t. | 143 t. | 5 |
| 2021 | - | 97 t. | 117 t. | 250 t. | 3 |
| 2020 | - | -115 t. | 72 t. | 133 t. | - |
| 2019 | - | -71 t. | 141 t. | 141 t. | - |
Official annual report
Keep an eye on Biogenity ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringAbout Biogenity ApS
Biogenity ApS is a Danish company of the type Anpartsselskab based in Aalborg Øst, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Kenneth Kastaniegaard and Louis Loeb. The board consists of Louis Loeb (chair) and Kenneth Kastaniegaard. The company is owned by L.Loeb Holding ApS and Kastaniegaard Holding ApS. According to the 2025 annual report, the company had an average of 4 employees. In 2025, the company reported a gross profit of DKK 1,387,873 and a net result of DKK -453,753 compared with DKK -342,877 the year before. Equity in the 2025 report amounted to DKK -189,867.